HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 22, No 01, January 2018 – Weighing the options       » Scientists close in on origin of SARS       » Chinese researchers map key protein in DNA repair with near-atomic resolution       » Ryzodeg reduces hypoglycaemia in type 2 diabetic fasting patients       » United States cancer drug costs increasing despite competition       » Eating yogurt may help reduce chronic inflammation in women      
INSIDE INDUSTRY
Cellectis and Servier to collaborate in allogeneic cell therapy

Cellectis, an expert of allogeneic CAR T-cell therapies has signed a strategic collaboration agreement with Servier, the first independent French pharmaceutical research company, to develop and commercialize novel product candidates targeting leukemia and solid tumors.

The partnership covers the development and potentially the commercialization of Cellectis' lead product candidate, UCART19. Engineered allogeneic CD19 T-cells currently stand out as a real therapeutic innovation for treating various types of leukemias and lymphomas.

The agreement also included research, development, and potentially the commercialization of five other product candidates targeting solid tumors.

Cellectis will be responsible for the R&D of certain product candidates through the end of Phase I. Servier may exercise an exclusive worldwide option for a license on each product candidate developed under the agreement. Upon exercising each option, Servier will be responsible for taking over clinical development, registration and commercialization of each product.

Mathieu Simon, M.D., Senior Vice-President at Cellectis stated, "Our alliance with the Servier Research Group is a real recognition of the value of our innovative approach to treating cancer. This partnership will provide Cellectis with substantial revenues to reach our goals in the biopharmaceutical field. Combining Cellectis' technical expertise with Servier's scientific, medical and financial resources will create an exciting new alliance to fuel the development of our unique, novel allogeneic cancer therapies, ultimately benefitting many patients around the world."

Jean-Pierre Abastado, Ph.D., Head of the Oncology Innovation Center at Servier, commented, "These original cell-based therapies will well complement Servier's innovative clinical oncology pipeline, which currently includes immunotherapeutic monoclonal antibodies, an HDAC inhibitor, kinase inhibitors, antiangiogenic and proapoptotic small molecules."

Emmanuel Canet, M.D., Ph.D., President of Servier R&D, stressed that "through this partnership, Servier is reinforcing its commitment to provide innovative therapeutic solutions for unmet needs in patients with serious illnesses."

Source: Business Wire

Click here for the complete issue.

NEWS CRUNCH  
news Biology of Ageing II - Impactful Interventions
news Separation of conjoined twins presents surgical and ethical challenges for MassGeneral Hospital for Children staff
news MIT Technology Review announces 2018's 10 'Innovators Under 35 Asia'
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Addressing the ageing population / Clinical trials
March:
Nutrition / Women in Science
April:
Digestive health / Intellectual property
May:
Asthma / Dental health
June:
Oncology / Biotech landscape in APAC
July:
Water management / Vaccination
August:
Regenerative medicine / Biotech start ups
September:
Digital healthcare / 3D printing
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy